Aim Immunotech Inc. (AIM) Stock Price & Analysis
Aim Immunotech Inc. (AIM) fell 22.34% to USD 0.4 as of June 10, 2026 at 04:43 UTC, according to Nexqual real-time market data.
AIM last closed at USD 0.52; the session ranged USD 0.37–0.49 on volume of 10,586,455 shares. Market capitalization is $9.80M, with a 52-week range of USD 0.21–19.74 (ASE). Source: Nexqual, June 10, 2026 at 04:43 UTC.
Key Statistics (as of June 10, 2026 at 04:43 UTC)
| Price | USD 0.4 |
|---|---|
| Change | ▼ 22.34% (down) |
| Previous Close | USD 0.52 |
| Open | USD 0.48 |
| Day Range | USD 0.37 – 0.49 |
| 52-Week Range | USD 0.21 – 19.74 |
| Volume | 10,586,455 shares |
| Market Cap | $9.80M |
| Exchange | ASE |
Technical Analysis (AIM)
Nexqual's technical model rates AIM "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 04:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 51.87 (neutral) |
| vs SMA50 | Below (USD 0.49) |
| MACD | 0.04 (positive) |
Analyst Ratings (AIM)
Wall Street analysts rate AIM "Strong Buy" based on 2 analysts, with a mean price target of USD 5.25 (range USD 1.5–9), per Nexqual as of June 10, 2026 at 04:43 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.25 |
| High Target | USD 9 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (AIM)
| EPS Estimate | USD -0.12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.69 vs est -0.37 ▼ miss |
| 2025-12-31 | USD -0.44 vs est -0.94 ▲ beat |
| 2025-09-30 | USD -1.57 vs est -0.98 ▼ miss |
| 2025-06-30 | USD -3.68 vs est -7.99 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:43 UTC.
Financials & Fundamentals (AIM)
| Total Revenue | $88,000 |
|---|---|
| Revenue Growth (YoY) | -53.30% |
| Gross Margin | -45.46% |
| Operating Margin | -14057.14% |
| Profit Margin | +0.00% |
| Current Ratio | 0.53 |
| Total Cash | $3.05M |
| Total Debt | $4.90M |
| Free Cash Flow | $-11.97M |
Source: Nexqual, June 10, 2026 at 04:43 UTC.
Financial Health Score (AIM)
Nexqual rates Aim Immunotech Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:43 UTC.
| Growth | Critical — Revenue -48% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $5M debt |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Mixed — No data |
Ownership (AIM)
| Insider Ownership | +1.98% |
|---|---|
| Institutional Ownership | +2.48% |
| Shares Outstanding | 24.33M |
| Float | 7.99M |
| Short % of Float | +3.79% |
Source: Nexqual, June 10, 2026 at 04:43 UTC.
Leadership (AIM)
Aim Immunotech Inc. is led by Thomas K. Equels Esq., J.D., M.S. (age 72), Executive Vice Chairman, CEO & President, per Nexqual as of June 10, 2026 at 04:43 UTC.
| Executive Vice Chairman, CEO & President | Thomas K. Equels Esq., J.D., M.S. (age 72) |
|---|---|
| Chief Financial Officer | Robert Dickey IV, B.A. (age 69) |
| COO, Executive Director of Governmental Relations, General Counsel & Secretary | Peter W. Rodino III, Esq. (age 74) |
| Director of Administration & Human Resources and Deputy Investor Relations Coordinator | Ann Marie E. Coverly |
From Aim Immunotech Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Partnerships
- Kellner is a Chartered Financial Analyst with over 50 years of investment experience and currently manages his personal and family investments after retiring in 2017 from his career as a portfolio manager at Fiduciary Management, Inc., an investment management firm that he founded in 1980.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AYTU | Aytu BioPharma, Inc. | USD 2.3 | ▲ 2.22% |
| CODX | Co-Diagnostics, Inc. | USD 4.5 | ▼ 20.07% |
| IBIO | iBio, Inc. | USD 1.7 | ▼ 6.59% |
| COCP | Cocrystal Pharma, Inc. | USD 1.02 | ▲ 6.25% |
| NNVC | NanoViricides, Inc. | USD 1.4 | ▲ 1.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:43 UTC. This page is informational and not investment advice.